Novel Platforms for Preclinical Antibody Discovery

11AM-12PM EDT | August 11, 2026

Antibodies are powerful preventive and therapeutic tools against microbes, cancers, autoimmune disorders, and many other diseases. However, traditional antibody discovery approaches often face major limitations, including low efficiency, high costs, high failure rates, logistical barriers, limited scalability, and long turnaround times.

We are excited to invite Dr. Ivelin Georgiev to present his work on novel wet-lab and AI-based platforms designed to make preclinical antibody discovery more effective and efficient.

In this webinar, Dr. Georgiev will discuss progress toward developing and validating integrated platforms for antibody discovery. He will highlight how these approaches can transform both the process and cost of identifying new monoclonal antibody drug candidates, while enabling the discovery of antibody phenotypes that have been challenging or even impossible to achieve using traditional methods.

Key points to be discussed during the session:

• How wet-lab and AI-based platforms can improve efficiency, scalability, and success rates in antibody discovery
• How integrated computational and experimental workflows can reduce cost, complexity, and turnaround time
• How next-generation platforms can uncover antibody phenotypes that traditional methods often miss

Ivelin Georgiev, PhD
Professor, Vanderbilt University

Dr. Georgiev received his Ph.D. in Computer Science from Duke University and later served as a staff scientist and co-head of Structural Bioinformatics at the Vaccine Research Center, NIH. He is currently a Professor at Vanderbilt University, with appointments in Pathology, Microbiology, and Immunology; Biochemistry; Biomedical Informatics; Computer Science; and Chemical and Biomolecular Engineering. He also directs the Vanderbilt Ph.D. Program in Chemical and Physical Biology and serves as an Associate Director for the Vanderbilt Institute for Infection, Immunology, and Inflammation. As founding Director of the Vanderbilt Center for Computational Microbiology and Immunology, he supports research, educational, and strategic efforts that apply computation to disease treatment, prevention, and human health. Dr. Georgiev has published over 100 peer-reviewed manuscripts in leading journals including Science, Nature, and Cell, and is an inventor on numerous issued patents.

For research use only. Not intended for any clinical use.